Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications

Table 6 Antidepressant prophylaxis

Ref.	n	Design	Antidepressant	Outcomes
Angelino et al[36]	-	Retrospective literature review	Citalopram; fluvoxamine	Prophylactic antidepressants might be well-considered for patients with a family history of - or previous episodes of - depression
Schaefer et al[57]	33	Prospective clinical trial	Citalopram	Pre-treatment of psychiatric patients with citalopram significantly reduced the incidence of IFN-induced MDD during the first 6 mo of antiviral treatment
Raison et al[59]	61	Double-blind, placebo-controlled clinical trial	Paroxetine	Data support the use of antidepressant pre-treatment in HCV patients with elevated depressive symptoms at baseline
Morasco et al[58]	33	Double-blind, placebo-controlled clinical trial	Paroxetine	A prophylactic approach to reduce IFN-α-induced depression may not be indicated in patients with HCV
Galvão-de Almeida et al[56]	-	Retrospective literature Review	Citalopram, paroxetine, escitalopram	Antidepressant prophylaxis may blunt the magnitude of depressive symptoms in HCV patients and raise the rates of treatment completion in those with psychiatric diagnosis
Morasco et al[60]	39	Double-blind, placebo-controlled clinical trial	Citalopram	Citalopram is not superior to placebo in preventing IFN-induced MDD

IFN: Interferon; MDD: Major depressive disorder; HCV: Hepatitis C virus.